Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PODD
stocks logo

PODD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
768.30M
+28.59%
1.461
+27.06%
714.43M
+25.56%
1.189
+16.53%
776.11M
+19.57%
1.432
+22.38%
Estimates Revision
The market is revising Upward the revenue expectations for Insulet Corporation (PODD) for FY2025, with the revenue forecasts being adjusted by 2.66% over the past three months. During the same period, the stock price has changed by -9.33%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.66%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.36%
In Past 3 Month
Stock Price
Go Down
down Image
-9.33%
In Past 3 Month
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 379.29 USD with a low forecast of 316.00 USD and a high forecast of 428.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 379.29 USD with a low forecast of 316.00 USD and a high forecast of 428.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 315.920
sliders
Low
316.00
Averages
379.29
High
428.00
Current: 315.920
sliders
Low
316.00
Averages
379.29
High
428.00
Canaccord
Buy
maintain
$428 -> $432
2025-11-24
Reason
Canaccord
Price Target
$428 -> $432
2025-11-24
maintain
Buy
Reason
Canaccord raised the firm's price target on Insulet to $432 from $428 and keeps a Buy rating on the shares. The firm updated its model to reflect the 2025-2028 financial outlook plan, which outlines revenue, adjusted operating margin, adjusted EPS, and free cash flow guidance for the company.
BTIG
Buy
maintain
$370 -> $380
2025-11-21
Reason
BTIG
Price Target
$370 -> $380
2025-11-21
maintain
Buy
Reason
BTIG raised the firm's price target on Insulet to $380 from $370 and keeps a Buy rating on the shares after the company's Investor Day presentation. Insulet aims to be "omnipresent" in type-1 and type-2 diabetes as it targets a "sustained multi-year growth", the analyst tells investors in a research note. BTIG adds it sees Insulet's long-range targets as achievable, and the firm is pleased to hear that the company is undertaking various initiatives to drive growth in both the near and long term.
RBC Capital
Shagun Singh
Outperform
maintain
$370 -> $380
2025-11-21
Reason
RBC Capital
Shagun Singh
Price Target
$370 -> $380
2025-11-21
maintain
Outperform
Reason
RBC Capital analyst Shagun Singh raised the firm's price target on Insulet to $380 from $370 and keeps an Outperform rating on the shares after the company's Investor Day presentation. The firm comes away from the event more bullish on Insulet's future prospects, including growth runway and market leadership in a highly under-penetrated end-market, the analyst tells investors in a research note. RBC is also raising its FY26 EPS view to $6.28 from $5.99 and its FY27 view to $8.03 from $7.27.
Truist
Richard Newitter
Buy
maintain
$390 -> $412
2025-11-21
Reason
Truist
Richard Newitter
Price Target
$390 -> $412
2025-11-21
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Insulet to $412 from $390 and keeps a Buy rating on the shares. The firm cites the company's Investor Day presentation outlining its 3-year outlook for revenue and profit, and believes that Insulet is well-positioned to maintain its lead in a rapidly growing patch category that is fueling the pump market expansion with still underpenetrated Type 1 and Type 2 diabetes categories, the analyst tells investors in a research note.
UBS
Neutral -> Buy
upgrade
$355 -> $400
2025-11-19
Reason
UBS
Price Target
$355 -> $400
2025-11-19
upgrade
Neutral -> Buy
Reason
UBS upgraded Insulet to Buy from Neutral with a price target of $400, up from $355, ahead of the analyst day. The firm believes the company can sustain its growth momentum through the end of the decade. Insulet's type 2 diabetes ramp will be meaningful enough to offset a changing competitive landscape, the analyst tells investors in a research note. UBS says the type 2 upside over the next 12-24 months gives it conviction to raise its sales growth estimates through 2028 to 17% annually.
Truist
Buy
maintain
$365 -> $390
2025-11-09
Reason
Truist
Price Target
$365 -> $390
2025-11-09
maintain
Buy
Reason
Truist raised the firm's price target on Insulet to $390 from $365 and keeps a Buy rating on the shares. The company posted another strong beat and raise on broad Omnipod 5 strength, the analyst tells investors in a research note. The firm remains confident in Insulet's prospects to sustain a well-above-average CAGR over the 2024-2028 period, Truist added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Insulet Corp (PODD.O) is 53.31, compared to its 5-year average forward P/E of 171.36. For a more detailed relative valuation and DCF analysis to assess Insulet Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
171.36
Current PE
53.31
Overvalued PE
283.72
Undervalued PE
59.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
63.14
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
91.47
Undervalued EV/EBITDA
34.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.93
Current PS
0.00
Overvalued PS
14.81
Undervalued PS
7.05
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PODD News & Events

Events Timeline

(ET)
2025-12-04
07:10:00
Insulet Receives FDA Clearance for Major Enhancements to Omnipod 5 System
select
2025-11-21 (ET)
2025-11-21
09:55:02
Significant Early Gainers in Liquid Options on November 21st
select
2025-11-20 (ET)
2025-11-20
12:33:27
Insulet Projects 20% Revenue CAGR and Over 25% Adjusted EPS CAGR from 2025 to 2028
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedInsulet Receives FDA Approval for Upgrades to Omnipod 5 Algorithm

  • FDA Clearance: Insulet has received FDA 510(k) clearance for enhancements to the Omnipod 5 Automated Insulin Delivery System, allowing for a new target glucose setting of 100 mg/dL.

  • Customization Range: The updates expand the customization range of the Omnipod 5 to six settings between 100-150 mg/dL in 10 mg/dL increments.

  • Projected Launch: The updated algorithm is expected to launch in the United States in the first half of 2026, targeting individuals aged 2 and older with type 1 diabetes and those aged 18 and older with type 2 diabetes.

  • Significant Advancement: Insulet's COO, Eric Benjamin, described this as the most significant algorithm advancement for the Omnipod 5 System since its initial launch in 2022.

[object Object]
Preview
3.5
12-04Newsfilter
Insulet Receives FDA Clearance for 100 mg/dL Target Glucose Setting Enhancements
  • Algorithm Upgrade: Insulet's Omnipod 5 system has received FDA 510(k) clearance for enhancements including a 100 mg/dL target glucose setting, which is expected to significantly improve clinical outcomes for diabetes patients by enhancing user experience and automated management capabilities.
  • Personalized Management: The new setting expands the target glucose range to 100-150 mg/dL, allowing healthcare providers to tailor insulin delivery more precisely, which directly impacts patients' blood sugar control and enhances their quality of life.
  • Clinical Outcome Improvement: Research indicates that lowering the target glucose is associated with increased time in range, with the Omnipod 5 system's upgrades anticipated to improve patients' time in the 70-180 mg/dL range by 11.8%, thereby boosting patients' confidence and management capabilities.
  • Market Outlook: The new features are expected to launch in the U.S. in the first half of 2026, targeting individuals aged 2 and older with type 1 diabetes and those aged 18 and older with type 2 diabetes, further solidifying Insulet's leadership position in the tubeless insulin pump market.
[object Object]
Preview
6.5
12-04NASDAQ.COM
Reasons to Consider Adding CONMED Stock to Your Portfolio Today

  • Growth Potential: CONMED Corporation is positioned for growth due to the rising adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, alongside increasing robotic procedure volumes and the expansion of Ambulatory Surgery Centers (ASCs).

  • Challenges and Delays: The company faces tariff-related gross margin pressures and delays in AirSeal adoption due to the integration of Intuitive Surgical’s dV5 system, which includes its own insufflation system, impacting immediate sales opportunities.

  • Supply Chain Improvements: Progress in supply chain recovery is expected to enhance product availability and support growth in the orthopedics business, although the full recovery may take several quarters.

  • Strategic Focus: A portfolio review is guiding CONMED to concentrate on high-return segments such as minimally invasive surgery and orthopedic soft-tissue repair, aiming to improve margins and long-term competitiveness.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Insulet Corp (PODD) stock price today?

The current price of PODD is 315.92 USD — it has increased 2.72 % in the last trading day.

arrow icon

What is Insulet Corp (PODD)'s business?

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

arrow icon

What is the price predicton of PODD Stock?

Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 379.29 USD with a low forecast of 316.00 USD and a high forecast of 428.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Insulet Corp (PODD)'s revenue for the last quarter?

Insulet Corp revenue for the last quarter amounts to 706.30M USD, increased 29.86 % YoY.

arrow icon

What is Insulet Corp (PODD)'s earnings per share (EPS) for the last quarter?

Insulet Corp. EPS for the last quarter amounts to 1.24 USD, increased 14.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Insulet Corp (PODD)'s fundamentals?

The market is revising Upward the revenue expectations for Insulet Corporation (PODD) for FY2025, with the revenue forecasts being adjusted by 2.66% over the past three months. During the same period, the stock price has changed by -9.33%.
arrow icon

How many employees does Insulet Corp (PODD). have?

Insulet Corp (PODD) has 3900 emplpoyees as of December 05 2025.

arrow icon

What is Insulet Corp (PODD) market cap?

Today PODD has the market capitalization of 22.22B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free